![]() |
|
|
Vol. 287, Issue 3, 1020-1028, December 1998
Department of Neuroscience, Troops in the Persian Gulf War have registered complaints consistent
with CNS dysfunction that emerged after returning from the Gulf. A
common experience among Persian Gulf War veterans was exposure to
pyridostigmine bromide (PB) for prophylaxis against nerve gas exposure.
To determine whether PB causes emergent CNS dysfunction, Wistar-Kyoto
(WKY) and Sprague-Dawley (SD) rats were given PB for 7 consecutive days
in their drinking water. The WKY, but not the SD, rats exhibited a
delayed-onset, persistently exaggerated startle response. The WKY rats
exhibited exaggerated startle responses that appeared 15 days after the
end of PB treatment and were still evident 22 days after the end of
treatment. Both the duration and the magnitude of the exaggerated
startle responses were related to the dosage of PB. The PB-treated rats
exhibited normal short-term and long-term habituation. However,
exaggerated startle responses were related to the development of
enhanced short-term sensitization. Treating the rats for a second time,
7 weeks after the end of the first PB treatment, induced an exaggerated
startle response that appeared sooner and dissipated faster than was
evident after the first PB treatment. Inasmuch as the WKY rat has
inherently low butyrylcholinesterase activity, a scavenger for PB,
these results suggest that prophylactic PB may influence CNS function in individuals with low butyrylcholinesterase activity. Elaboration of
the factors that mediate enhanced sensitization in the WKY rat may
provide insight into some of the complaints registered by veterans of
the Persian Gulf War.
0022-3565/98/2873-1020$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 1998 by The American Society for Pharmacology and Experimental Therapeutics
This article has been cited by other articles:
![]() |
O. U. Scremin, T.-M. Shih, L. Huynh, M. Roch, R. Booth, and D. J. Jenden Delayed Neurologic and Behavioral Effects of Subtoxic Doses of Cholinesterase Inhibitors J. Pharmacol. Exp. Ther., March 1, 2003; 304(3): 1111 - 1119. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. D. Santos, E. F. R. Pereira, Y. Aracava, N. G. Castro, W. P. Fawcett, W. R. Randall, and E. X. Albuquerque Low Concentrations of Pyridostigmine Prevent Soman-Induced Inhibition of GABAergic Transmission in the Central Nervous System: Involvement of Muscarinic Receptors J. Pharmacol. Exp. Ther., January 1, 2003; 304(1): 254 - 265. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Abou-Donia, A. M. Dechkovskaia, L. B. Goldstein, S. L. Bullman, and W. A. Khan Sensorimotor Deficit and Cholinergic Changes following Coexposure with Pyridostigmine Bromide and Sarin in Rats Toxicol. Sci., March 1, 2002; 66(1): 148 - 158. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. B. Abou-Donia, L. B. Goldstein, K. H. Jones, A. A. Abdel-Rahman, T. V. Damodaran, A. M. Dechkovskaia, S. L. Bullman, B. E. Amir, and W. A. Khan Locomotor and Sensorimotor Performance Deficit in Rats following Exposure to Pyridostigmine Bromide, DEET, and Permethrin, Alone and in Combination Toxicol. Sci., April 1, 2001; 60(2): 305 - 314. [Abstract] [Full Text] [PDF] |
||||